Toronto Dominion Bank Bei Gene, Ltd. Transaction History

Toronto Dominion Bank

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Feb 14, 2024	BUY	$179.87 - $225.13 $37,412 - $46,827	208 Added 166.4%	333 $59,000
Q3 2023 Nov 14, 2023	BUY	$179.87 - $225.13 $37,412 - $46,827	208 Added 166.4%	333 $59,000
Q2 2023 Feb 14, 2024	SELL	$178.3 - $266.78 $37,086 - $55,490	-208 Reduced 62.46%	125 $22,000
Q1 2023 May 11, 2023	BUY	$215.53 - $274.5 $26,941 - $34,312	125 New	125 $27,000

254

45.1M

131K

95.6K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $23.5B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Toronto Dominion Bank, based on Form 13F filings with the SEC.

Stay updated on Toronto Dominion Bank with notifications on news.